Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor (PNET)
Conditions
Brief summary
This clinical trial studies genetic biomarkers from saliva samples in patients with Ewing sarcoma. Studying samples of saliva from patients with cancer in the laboratory may help doctors learn more about changes that occur in deoxyribonucleic acid (DNA) and identify biomarkers related to cancer.
Detailed description
PRIMARY OBJECTIVES: I. To determine the association between the length of Ewing sarcoma breakpoint region 1-Friend leukemia virus integration 1 (EWS-FLI1) fusion protein binding sites (microsatellites) and risk of Ewing's sarcoma (ES). II. To determine the frequency and commonality of Caucasian ancestral markers in cases of ES self-identified as non-Caucasian (African-American, Asian, Hispanic). III. To determine the association between genomic variants in ES-related genes and hernia development (i.e. the integrin signaling pathway) and risk of ES. OUTLINE: Genomic DNA is extracted from participants' saliva samples and analyzed for expression of EWS-FLI1 and other ES-target genes.
Interventions
OTHERlaboratory biomarker analysis
Correlative studies
OTHERquestionnaire administration
Ancillary studies
Sponsors
National Cancer Institute (NCI)
Children's Oncology Group
Study design
Observational model
FAMILY_BASED
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
Yes
Inclusion criteria
* The patient is enrolled on ACCRN07 * The patient has a diagnosis of Ewing Sarcoma (International Classification of Diseases \[ICD\] code morphology 9260; topography C40.0-C41.9, C76.0-C76.8, C80.9) and is registered with Children's Oncology Group (COG) by a North American member institution * The patient must be diagnosed with Ewing sarcoma between December 24, 2007 and December 31, 2015 * The patient must have at least one biological parent alive and willing to participate * All questionnaire respondents must understand English or Spanish * Concomitant treatment on a therapeutic trial is not required
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Main effect of gene polymorphisms | Up to 5 years | Risk ratios (RR) for the main effect of gene polymorphisms will be calculated using log-linear models. RRs and 95% confidence intervals for the gene-environment interaction are calculated by stratifying the likelihood according to case exposure. |
Countries
United States
Outcome results
None listed